Nature Communications (Mar 2019)
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
- Luigi Formisano,
- Yao Lu,
- Alberto Servetto,
- Ariella B. Hanker,
- Valerie M. Jansen,
- Joshua A. Bauer,
- Dhivya R. Sudhan,
- Angel L. Guerrero-Zotano,
- Sarah Croessmann,
- Yan Guo,
- Paula Gonzalez Ericsson,
- Kyung-min Lee,
- Mellissa J. Nixon,
- Luis J. Schwarz,
- Melinda E. Sanders,
- Teresa C. Dugger,
- Marcelo Rocha Cruz,
- Amir Behdad,
- Massimo Cristofanilli,
- Aditya Bardia,
- Joyce O’Shaughnessy,
- Rebecca J. Nagy,
- Richard B. Lanman,
- Nadia Solovieff,
- Wei He,
- Michelle Miller,
- Fei Su,
- Yu Shyr,
- Ingrid A. Mayer,
- Justin M. Balko,
- Carlos L. Arteaga
Affiliations
- Luigi Formisano
- Departments of Medicine, Vanderbilt University Medical Center
- Yao Lu
- Departments of Medicine, Vanderbilt University Medical Center
- Alberto Servetto
- UTSW Simmons Cancer Center
- Ariella B. Hanker
- Departments of Medicine, Vanderbilt University Medical Center
- Valerie M. Jansen
- Departments of Medicine, Vanderbilt University Medical Center
- Joshua A. Bauer
- Departments of Biochemistry, Vanderbilt University Medical Center
- Dhivya R. Sudhan
- Departments of Medicine, Vanderbilt University Medical Center
- Angel L. Guerrero-Zotano
- Departments of Medicine, Vanderbilt University Medical Center
- Sarah Croessmann
- Departments of Medicine, Vanderbilt University Medical Center
- Yan Guo
- Vanderbilt Center for Quantitative Sciences, Vanderbilt University School of Medicine
- Paula Gonzalez Ericsson
- Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
- Kyung-min Lee
- Departments of Medicine, Vanderbilt University Medical Center
- Mellissa J. Nixon
- Departments of Medicine, Vanderbilt University Medical Center
- Luis J. Schwarz
- Departments of Medicine, Vanderbilt University Medical Center
- Melinda E. Sanders
- Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
- Teresa C. Dugger
- Departments of Medicine, Vanderbilt University Medical Center
- Marcelo Rocha Cruz
- Robert H Lurie Comprehensive Cancer Center
- Amir Behdad
- Robert H Lurie Comprehensive Cancer Center
- Massimo Cristofanilli
- Robert H Lurie Comprehensive Cancer Center
- Aditya Bardia
- Massachusetts General Hospital Cancer Center, Harvard Medical School
- Joyce O’Shaughnessy
- Baylor University Medical Center, Texas Oncology, , US Oncology
- Rebecca J. Nagy
- Guardant Health
- Richard B. Lanman
- Guardant Health
- Nadia Solovieff
- Novartis Institutes for Biomedical Research
- Wei He
- Novartis Institutes for Biomedical Research
- Michelle Miller
- Novartis Pharmaceuticals Corporation
- Fei Su
- Novartis Pharmaceuticals Corporation
- Yu Shyr
- Vanderbilt Center for Quantitative Sciences, Vanderbilt University School of Medicine
- Ingrid A. Mayer
- Departments of Medicine, Vanderbilt University Medical Center
- Justin M. Balko
- Departments of Medicine, Vanderbilt University Medical Center
- Carlos L. Arteaga
- Departments of Medicine, Vanderbilt University Medical Center
- DOI
- https://doi.org/10.1038/s41467-019-09068-2
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 14
Abstract
Era+ breast cancer patients often develop resistance to endocrine therapy. Here, the authors show that FGFR1 amplification is a resistance mechanism to CDK4/6 inhibitor and endocrine therapy and that combined treatment with FGFR, CDK4/6, and anti-estrogens is a potential therapeutic strategy in Era+ breast cancer tumors.
